Mangafodipir trisodium_product_DataBase

Bioactivity	Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy[1][2].
Invitro	Mangafodipir trisodium (40, 200 和 1000 μM) 抑制 H2O2 对 HGrC 细胞活力的影响[3]。Mangafodipir trisodium (200 和 1000 μM) 减少顺铂诱导的 HGrC 细胞凋亡[3]。
In Vivo	Mangafodipir trisodium (10 mg/kg；腹腔注射，一次) 显示出对顺铂和紫杉醇引起的小鼠卵巢损伤的保护作用[3]。 Animal Model:
Name	Mangafodipir trisodium
CAS	140678-14-4
Formula	C22H27MnN4Na3O14P2
Molar Mass	757.32
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Karlsson JOG, et al. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017 Aug;10(4):641-649. [2]. Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl. 1998;415:1-31. [3]. Qin Y, et al. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018 Oct 27;16(1):106.

PeptideDB